|
Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC). |
|
|
Employment - Exact Sciences (I); Myriad Genetics (I) |
Honoraria - Grand Rounds in Urology; Ideology Health; Onviv; PeerView; PrecisCa; UpToDate |
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Kura Oncology; Loxo/Lilly; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial |
Speakers' Bureau - Astellas Pharma; AVEO; Bayer; Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Janssen Oncology; Medscape; Merck; Natera; Pfizer; Research to Practice; Seagen |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Sumitomo Pharma Oncology (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb |
Other Relationship - Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Merck; Mereo BioPharma; QED Therapeutics |
|
|
Honoraria - AAA HealthCare; Almirall; Astellas Pharma; AstraZeneca Spain; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer |
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer; Recordati |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Merck; MSD Oncology; Pfizer; Roche |
|
|
Honoraria - Bristol Myers Squibb Foundation; Urogen pharma |
Consulting or Advisory Role - Merck; Urogen pharma |
Speakers' Bureau - Bristol-Myers Squibb/Celgene |
Research Funding - Urogen pharma |
Expert Testimony - GlaxoSmithKline |
|
|
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen |
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen |
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate author royalty |
Travel, Accommodations, Expenses - Pfizer |
|
|
Honoraria - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; Exelixis/Ipsen; Ferring; Gilead Sciences; Immunomedics; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; MSD Oncology; Novartis; Orion; Pfizer; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Thermosome |
Consulting or Advisory Role - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; BioClin Therapeutics; BioSyn Healthy Pharma; Bristol-Myers Squibb; Eisai; Ferring; Gilead Sciences; GlaxoSmithKline; Immunomedics/Gilead; Ipsen; Janssen; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Orion Health; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Takeda; Thermosome |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Ipsen; Janssen; Merck Serono; Pfizer; Roche; Roche/Genentech; Sanofi |
|
|
Employment - Moderna Therapeutics |
Stock and Other Ownership Interests - 2seventy bio; Bluebird Bio; Moderna Therapeutics |
Consulting or Advisory Role - Stellular Bio |
|
|
Employment - Bristol Myers Squibb Foundation; Moderna Therapeutics |
Stock and Other Ownership Interests - Moderna Therapeutics |
|
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen |
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche |